VEGFA and choroidal neovascularization: Bevacizumab (Avastin) and ranibizumab (Lucentis) are a monoclonal antibody and an antibody fragment, respectively, which bind to VEGF-A to inhibit VEGF signaling in choroidal neovascularization (CNV) [93].